ITI-007 in the treatment of schizophrenia: from novel pharmacology to clinical outcomes

ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial

(2016) Jeffrey A. Lieberman et al.   BIOLOGICAL PSYCHIATRY

ITI-007 demonstrates brain occupancy at serotonin 5-HT2A and dopamine D2 receptors and serotonin transporters using positron emission tomography in healthy volunteers

(2015) Robert E. Davis et al.   PSYCHOPHARMACOLOGY

A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia

(2015) John M. Kane et al.   SCHIZOPHRENIA RESEARCH

Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder

(2015) Christoph U. Correll et al.   World Psychiatry

Cardiovascular and cerebrovascular risk factors and events associated with second-generation antipsychotic compared to antidepressant use in a non-elderly adult sample: results from a claims-based inception cohort study

(2015) Christoph U. Correll et al.   World Psychiatry

Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia

(2014) Maren Carbon et al.   CNS SPECTRUMS

Emerging drugs for schizophrenia: an update

(2014) Luisa-Sophie Köster et al.   EXPERT OPINION ON EMERGING DRUGS

Discovery of a Tetracyclic Quinoxaline Derivative as a Potent and Orally Active Multifunctional Drug Candidate for the Treatment of Neuropsychiatric and Neurological Disorders

(2014) Peng Li et al.   JOURNAL OF MEDICINAL CHEMISTRY

Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission

(2014) Gretchen L. Snyder et al.   PSYCHOPHARMACOLOGY

Antipsychotic-Induced Metabolic and Cardiovascular Side Effects in Schizophrenia: A Novel Mechanistic Hypothesis

(2013) Giulio Scigliano et al.   CNS DRUGS

5-Hydroxytryptamine 2A receptor antagonists as potential treatment for psychiatric disorders

(2013) Tiago A Mestre et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Reviewing the ketamine model for schizophrenia

(2013) Joel Frohlich et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis

(2013) Stefan Leucht et al.   LANCET

Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia

(2013) Stephen R. Marder et al.   SCHIZOPHRENIA RESEARCH

Pomaglumetad methionil: No significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo

(2013) Virginia L. Stauffer et al.   SCHIZOPHRENIA RESEARCH

Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies

(2013) John M. Kane et al.   World Psychiatry

Placebo-related effects in clinical trials in schizophrenia: what is driving this phenomenon and what can be done to minimize it?

(2012) Larry Alphs et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Exploratory Analyses of Efficacy Data From Schizophrenia Trials in Support of New Drug Applications Submitted to the US Food and Drug Administration

(2012) Ni A. Khin et al.   JOURNAL OF CLINICAL PSYCHIATRY

Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010

(2012) Joshua A Salomon et al.   LANCET

Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010

(2012) Christopher J L Murray et al.   LANCET

Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010

(2012) Theo Vos et al.   LANCET

A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010

(2012) Stephen S Lim et al.   LANCET

Lurasidone in the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo- and Olanzapine-Controlled Study

(2011) Herbert Y. Meltzer et al.   AMERICAN JOURNAL OF PSYCHIATRY

Serotonin 2A receptor antagonists for treatment of schizophrenia

(2011) Bjørn H Ebdrup et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Mid-Term and Long-Term Efficacy and Effectiveness of Antipsychotic Medications for Schizophrenia

(2011) Ira D. Glick et al.   JOURNAL OF CLINICAL PSYCHIATRY

Metabolic and cardiovascular adverse effects associated with antipsychotic drugs

(2011) Marc De Hert et al.   Nature Reviews Endocrinology

Increased Serotonin 2A Receptor Availability in the Orbitofrontal Cortex of Physically Aggressive Personality Disordered Patients

(2010) Daniel R. Rosell et al.   BIOLOGICAL PSYCHIATRY

From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics

(2010) C.U. Correll   EUROPEAN PSYCHIATRY

Past and Present Progress in the Pharmacologic Treatment of Schizophrenia

(2010) John M. Kane et al.   JOURNAL OF CLINICAL PSYCHIATRY

Antipsychotic drugs and obesity

(2010) Christoph U. Correll et al.   TRENDS IN MOLECULAR MEDICINE

Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents

(2009) Christoph U. Correll   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

The Dopamine Hypothesis of Schizophrenia: Version III--The Final Common Pathway

(2009) O. D. Howes et al.   SCHIZOPHRENIA BULLETIN

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis

(2008) Stefan Leucht et al.   LANCET